Quality of life for CLL patients on acalabrutinib
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at quality of life in people with CLL who are taking acalabrutinib for the first time. It uses data already collected from a real-world database to see how patients feel and function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have chronic lymphocytic leukemia (CLL) and have never been treated for it before
- You are 18 years or older
- You have taken the drug acalabrutinib alone or with obinutuzumab
- You are part of the PLATON database (a French registry)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how acalabrutinib, a targeted therapy for chronic lymphocytic leukemia (CLL), works in real-life settings in Spain. It aims to see how well it helps people who are starting treatment for the first time or switching due to side effects.
This study follows people with CLL who are starting acalabrutinib (a targeted pill) for the first time, either as their first treatment or after previous therapies. The goal is to see how well it works in everyday medical practice.
This Phase 2 trial studies whether acalabrutinib, and optionally adding obinutuzumab, can control early-stage chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It aims to see how well these treatments work and how safe they are in people who have not had prior treatment.
This trial tests whether taking venetoclax on an intermittent schedule (not every day) works as well as taking it continuously when combined with acalabrutinib for people with untreated CLL or SLL. It aims to find a treatment approach that might be just as effective but with fewer side effects.
This Phase 2 trial studies how well acalabrutinib works when combined with either venetoclax or obinutuzumab in people with untreated chronic lymphocytic leukemia (CLL). It aims to improve disease control while checking safety and tolerability.
This observational study follows adults in the UK who started acalabrutinib through an early access program for chronic lymphocytic leukemia (CLL). It aims to learn what happens in real-world care after starting the medicine.
Hear when a new Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.